top of page

2025 AWARD RECIPIENTS

EUROPCR 2025

VisCardia

President & CEO of VisCardia, Peter Bauer, shares his innovation with Dr. Yohei Ohno and Tom DeHaan. VisCardia won the Foundation's Award for Innovation in Cardiology at PCR 2025 Innovators Day. 

20251025_165016_edited.jpg

Smart implant for pressure-guided heart failure decongestion wins TCT 2025 Shark Tank prize

Cardiovascularnews.com October 26, 2025 - Relief Cardiovascular—developer of a smart implant designed to haemodynamically monitor and treat congestion in heart failure—has been named as the recipient of the Shark Tank innovation prize at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) conference (25–28 October, San Francisco, USA).

The Relief system was one of six technologies competing for the prize, which included a next-generation transcatheter Endo-Bentall system (P&F Products), a leaflet resection and extraction system from Tresquare, circulatory decongestion support (Pulnovo Medical), and artificial intelligence (AI)-guided robotic imaging navigation platform (Laza Medical). Pathwai, a next-generation cardiac screening technology, was the runner up in the competition.

 

The Relief system features a pressure-guided active valve implanted in the vena cava which is designed to dynamically reduce cardiac preload and enhance renal vein flow. The technology integrates haemodynamic monitoring with an adaptive haemodynamic therapy into a single transcatheter implant system.

 

Relief Cardiovascular recently announced the successful first-in-human use of the system, performed in the Republic of Georgia as part of a feasibility study evaluating the device’s safety. Implantations were carried out by Tamaz Shaburishvili, Levan Sulakvelidze, and Gigi Shaburishvili at Tbilisi Heart and Vascular Center (Tblisi, Georgia), with support from Alex Rothman University of Sheffield (Sheffield, UK). “Managing heart failure often feels like aiming at a moving target,” said Rothman. “In small cohorts of patients, clinical teams track remotely measured pressures and continuously adjust medications to optimise therapy, which has been proven to improve outcomes. However, scaling this manual approach to the millions of heart failure patients in need is a challenge. In these first-in-human procedures, we demonstrated the Relief System’s ability to remotely measure cardiac preload and produce a meaningful reduction in cardiac preload and renal afterload when desired. These procedures represent a major step forward in managing congestion at scale with an intelligent implantable therapeutic system.”

 

The TCT Shark Tank Innovation Competition is delivered through a partnership with the Jon DeHaan Foundation, with the winning entry receiving a US$200,000 award. The competition aims to identify and showcase groundbreaking concepts in modern cardiovascular medicine.

Watch the interview with Dr. Robert Schwartz and Dr. Alexander Rothman.

image002_edited.jpg

WINNER ANNOUNCED! Relaax Medical Takes Home the Jon DeHaan Foundation Award and $200,000!

Israel, December 9, 2025, /ICI - Innovations in Cardiovascular Interventions Meeting Facebook/--The ICI Meeting just concluded one of its major highlights by awarding the prestigious John DeHaan Award to Relaax Medical (a Nidus Biomedical company), presented by Stanton Rowe.

The Breakthrough: Relaax Medical developed a novel solution to prevent stroke in AF patients by treating the Left Atrial Appendage (LAA). Their method uses a controlled shunt to ensure continuous blood flow, stopping the dangerous clot formation.

This $200,000 award supports the development of crucial, high-impact medical technology. "We are proud to see competitors from all over the world view Israel as the central platform for innovation in cardiology." - Prof. Chaim Lotan & Prof. Rafi Beyar.

A huge thank you to all the startups who participated and applied this year, demonstrating the incredible depth of global cardiovascular innovation!

Congratulations to Relaax Medical! This is an incredible moment for the ICI 30th Anniversary!

©2019 by Jon Holden DeHaan Foundation

bottom of page